0.31%QQQQ 43.45 
0.48%XLF 21.74 3.62%
The Global Business News Leader | Saturday, 6 Sep 2008
- EQUITY MARKETS
- BONDS AND RATES
- FOREX
- COMMODITIES
- LANGUAGES
- FUNDS
- RETIREMENT
- TAXES
- INSURANCE
- LANGUAGES
- MOVIE
- MUSIC
- TV
- CELEBRITIES
- LANGUAGES
GENENTECH INC
DNA (NYSE)
$ 96.64 
Change: +0.14 +0.14% | Volume: 5,146,072
Change: +0.14 +0.14% | Volume: 5,146,072
GENENTECH INC - Fundamental Profile
Company Information
| Ticker Symbol: | DNA |
|---|---|
| Exchange: | NYSE |
| Contact Info: | 1 DNA Way South San Francisco CA 94080 650-225-1000 |
| CEO/President: | Arthur D. Levinson Ph.D. |
| Industry: | Medical - Biomedical / Standard Industry Code: 2834 |
| Description: | Genentech, Inc. is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. A considerable number of the currently approved biotechnology products originated from or are based on Genentech science. Genentech manufactures and commercializes multiple biotechnology products and licenses several additional products to other companies. Genentech\'s mission is to be the leading biotechnology company, using human genetic information to develop novel medicines for serious and life-threatening diseases. |
Share Information
| Shares Outstanding: | 1,050,890 (000) | Market Value: | 101,870,224 ($000) |
|---|---|---|---|
| Percentage of Inst.Shareholders: | 39.88% | Number of Inst.Shareholders: | 0.90% |
| Last Quarter Sales: | 3236.00 ($Mil.) | Last Quarter Net Income: | 782.00 ($Mil.) |
| Last Quarter EPS: | 0.75 | P/E Ratio: | 35 |
| Most Recent Earnings: | 0.82 on 07/14/08 | Earnings Per Share: | 2.70 |
| Most Recent Split: | 2-1 on 05/13/04 | Annual Dividend Rate: | 0 |
| Most Recent Dividend: | Annual Dividend Yield: | 0% |
Data Provided By Barchart.com
CoreData does not represent, warrant, or guarantee completeness, accuracy or timeliness of its data, and shall have no liability of any kind whatsoever to any party on account of any incompleteness of, inaccuracies in or untimeliness of the CoreData content provided hereunder, or for any delay in reporting such data. CoreData expressly disclaims all warranties of fitness of the CoreData content or computations and analyses thereof for a particular purpose or use.
Most Popular 
DNA
Companies
IBT
- Biotech buyout action likely to continue
- Genentech retention plan to cost $371 million
- King says Alpharma rebuffed a $1.4B buyout bid
- Roche plans to close 1,000-worker California lab
- Novartis drug receives funding approval
- Early Glance: Biotechnology companies
- Study outcome won't sway company on eye drug
- FDA orders stronger warnings for 4 arthritis drugs
- Sony recalls 73,000 Vaio notebook computers
- GM pledges to boost recycling at its factories
- Ahead of the Bell: Analyst sees solar risk
- Lehman shares rebound as analyst confirms rating
- Cemex shares slip as analyst cuts price target
- Investors reach compromise at TNK-BP
- Sell the First of May, Return after Labor Day
- Sarah Palins speech seen by more than 40 Million on TV
- Jonas Brothers Upcoming TV Series Changes Theme
- Natural Gas Weekly Update
- Sarah Palins Teen daughter Bristol and Boyfriend attend Republican Convention
- Gene Simmons sued over Indycar deal
- Gold Investments Market Update - Gold Fell Some 50% in Middle of 1970s Bull Market, Prior to Rising 800%
Top Competitors
| AMGEN |  |
+30.20 | 60.88 |
| AMYLIN PHARMA I |  |
-55.90 | 21.48 |
| GILEAD SCIENCES | |
+22.60 | 49.98 |
| BIOGEN IDEC INC | |
-21.40 | 48.16 |
| GENENTECH INC | |
+33.70 | 96.50 |
Partners  
|
© 2008 The Ibtimes Company. All Rights Reserved. Terms of service | Privacy Policy | Advertising | About Us | Contact Us | Archives